Hong Kong Stock Announces Nuggets | Kyoho New Energy's equity power generation capacity in November was 697.23 GWh, up 7.77% year on year
Important matters:
Chuangsheng Group-B (06628): Chuangsheng Pharmaceutical announced updated efficacy data on Osemitamab triple therapy for first-line treatment of gastric or gastroesophageal adenocarcinoma in ESMO Asia (Transtar102)
Power Development (01277) plans to acquire 100% of Taiyuan's on-site shares for 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan
Cinda Biotech (01801) completes global strategic partnership with Takeda Pharmaceuticals and issues 6.913,800 shares under general license
Yasheng Pharmaceutical-B (06855) Global Registration Phase III Clinical Study for Nellick® First-Line Treatment Ph+ ALL was approved by the US FDA and European EMA
Biosetu-B (02315) business partner IDEAYA obtained IND approval from the US Food and Drug Administration for IDE034
Jingfang Pharmaceutical-B (02595): The registered clinical trial of GFH375 for the treatment of metastatic pancreatic cancer was launched at the first research center as the world's first phase III study of single-agent controlled chemotherapy with an oral KRAS G12D inhibitor
A subsidiary of Xishangbeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental business cooperation in designated cities under the “joint name store” model
International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong's Antarctic Light to seize growth opportunities in the IC chip market
CSPC Group (01093): GLP-1/GIP receptor bidirectional agonist polypeptide injection approved for clinical trials in the US
MIRXES-B (02629) plans to jointly build an AI-enabled and innovative “integrated diagnosis and treatment” research and industrialization platform with Jingtai Technology
Zhengtong Auto (01728) plans to spend a total of about 816 million yuan to acquire the Xiamen Cinda 4S dealership and automobile sales and export business
Guorui Life (00108) plans to acquire Beijing Chunyu Tianxia Software's total issued share capital of about 78.3% for 269 million yuan
Cinda Biotech (01801): Seven innovative products (including new indications), including Dabershu® and Xinbimin®, were successfully included in the 2025 National Medical Insurance Drug Catalogue
Peijia Medical-B (09996): The State Drug Administration accepted the registration application for the TaurusNXT® “non-formaldehyde crosslinked” dry valve transcatheter aortic valve replacement system
Fosun Pharmaceutical (02196) drugs are newly included in the national medical insurance catalogue and commercial insurance innovative drug catalogue
Junshi Biotech (01877): New indications for Tuoyi® and inclusion of Junshida® in the national health insurance catalogue
Weilizhibo-B (09887): LBL-034 clinical data released at the 67th ASH Annual Meeting
Kangfang Biotech (09926)'s 5 marketed drugs have all been successfully included in the latest edition of the National Medical Insurance Drug Catalogue
Fu Hong Han Lin (02696): Futurin® (vorbesilil citrate capsules) was included in the national medical insurance drug catalogue
Five new products of Luye Pharmaceutical (02186) were successfully included in the 2025 National Medical Insurance Drug Catalogue or Commercial Insurance Innovative Drug Catalogue
Yinnuo Pharmaceutical-B (02591) core products included in the “National Medical Insurance Drug Catalogue”
Operating performance:
Poly Real Estate Group (00119)'s contract sales amount for the first 11 months was about 47.7 billion yuan, down 8.45% year on year
Guangzhou Automobile Group (02238) sold about 179,700 vehicles in November, down 9.72% year on year
The equity power generation capacity of Xiehe New Energy (00182) in November was 697.23 GWh, up 7.77% year on year